Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 101–200 of 1,001
Barber, T. M., Kenkre, J. S., Garnett, C., Scott, R., Byrne, J. V., & Wass, J. A. H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04136.x · Cited by 72
Self-citationThe Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology
Auriemma, R. S., Vecchio, G. D., Scairati, R., Pirchio, R., Liccardi, A., Verde, N., de Angelis, C., Menafra, D., Pivonello, C., Conforti, A., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.594370 · Cited by 85
“However, in asymptomatic patients with hyperprolactinemia, there is no absolute requirement to treat (65).”
BackgroundEGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
Cooper, O. B., Bonert, V. S., Rudnick, J. D., Pressman, B. D., Lo, J., Salvatori, R., Yuen, K. C. J., Fleseriu, M., & Melmed, S. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa805 · Cited by 72
Self-citationNonfunctioning pituitary tumors
Molitch, M. E. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00012-5 · Cited by 73
“Therefore, prolactinomas would generally be treated with dopamine agonists and those producing GH or ACTH would be treated with surgery (Biller et al., 2008; Melmed et al., 2009, 2011).”
BackgroundDopamine agonist resistant prolactinomas: any alternative medical treatment?
Souteiro, P., & Karavitaki, N. (2019) · Pituitary · doi:10.1007/s11102-019-00987-3 · Cited by 81
Swearingen, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3237 · Cited by 71
“It has been replaced in the initial treatment of prolactinomas by dopamine agonist therapy for most patients (72).”
BackgroundThe Association Between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis
Yang, H., Di, J., Pan, J., Yu, R., Teng, Y., Cai, Z., & Deng, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00263 · Cited by 91
“If serum PRL is over >25 μg/L (or 530 mIu/L), it is considered to be hyperprolactinemia (36, 37).”
BackgroundCozzi, R. C., Ambrosio, M. R., Attanasio, R., Battista, C., Bozzao, A., Caputo, M., CICCARELLI, E., Marinis, L. D., Menis, E. D., Fustini, M. F., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0977 · Cited by 77
Wang, S., Wang, L., Yao, Y., Feng, F., Yang, H., Liang, Z., Deng, K., You, H., Sun, J. H., Xing, B., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13354 · Cited by 75
Seppä, S., Kuiri‐Hänninen, T., Holopainen, E., & Voutilainen, R. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1487 · Cited by 95
Lu, Y., Xiong, J., Daoying, G., & Yin, B. (2015) · Journal of Neuroradiology · doi:10.1016/j.neurad.2015.09.003 · Cited by 69
Pituitary tumors: epidemiology and clinical presentation spectrum
Castro, M. A., Berrocal, V. R., & Corrales, E. P. (2020) · HORMONES · doi:10.1007/s42000-019-00168-8 · Cited by 90
Hu, J., Zheng, X., Zhang, W., & Yang, H. (2014) · Pituitary · doi:10.1007/s11102-014-0617-2 · Cited by 68
Prolactin has a pathogenic role in systemic lupus erythematosus
Jara, L. J., Medina, G., Saavedra, M. Á., Lastra, O. L. V., Aguilar, H. T., Navarro, C., Mercado, M. V.-D., & Espinoza, L. R. (2017) · Immunologic Research · doi:10.1007/s12026-016-8891-x · Cited by 72
“For treating HPRL in SLE patients caused by medications, renal failure and adenomas, among others, should be first ruled out and managed according to established guidelines [121].”
BackgroundPituitary apoplexy in pregnancy: A case series and literature review
Grand’Maison, S., Weber, F., Bédard, M., Mahone, M., & Godbout, A. (2015) · Obstetric Medicine · doi:10.1177/1753495x15598917 · Cited by 70
“This summary have taken into account the recommendations made by the Endocrine Society for diagnosis and treatment of hyperprolactinemia – see Melmed et al..(38) 42% 31% Medical treatment with bromocriptine or cabergoline 14%”
MethodPuberty and its disorders in the female
Rosenfield, R. L., Cooke, D. W., & Radovick, S. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00024-x · Cited by 74
Labad, J. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.11.028 · Cited by 73
Anatomy, Physiology, and Laboratory Evaluation of the Pituitary Gland
Hong, G. K., Payne, S. C., & Jane, J. A. (2015) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2015.09.002 · Cited by 74
Evaluation and management of galactorrhea.
Huang, W., & Molitch, M. E. (2012) · PubMed · Cited by 88
Molecular and Clinical Spectrum of Primary Hyperparathyroidism
Jha, S., & Simonds, W. F. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad009 · Cited by 80
Hyperprolactinemia and prolactinoma
Romijn, J. A. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00013-7 · Cited by 73
Xia, M. Y., Lou, X., Lin, S., & Wu, Z. B. (2017) · Endocrine · doi:10.1007/s12020-017-1444-9 · Cited by 65
Wang, C., Tan, C., Wen, Y., Zhang, D., Li, G., Chang, L., Su, J., & Wang, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1694-y · Cited by 68
Woodmansee, W. W., Carmichael, J. D., Kelly, D. F., & Katznelson, L. J. (2015) · Endocrine Practice · doi:10.4158/ep14541.dscr · Cited by 69
Soto‐Pedre, E., Newey, P. J., Bevan, J. S., Greig, N., & Leese, G. (2016) · Clinical Endocrinology · doi:10.1111/cen.13156 · Cited by 66
Brown, R. S. E., Khant Aung, Z., Phillipps, H. R., Barad, Z., Lein, H.-J., Boehm, U., Szawka, R. E., & Grattan, D. R. (2019) · Endocrinology · doi:10.1210/en.2019-00038 · Cited by 62
Pituitary Adenomas: From Diagnosis to Therapeutics
Banskota, S., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050494 · Cited by 85
Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha, S., Stokes, V. J., Karavitaki, N., & Grossman, A. B. (2015) · Endocrine · doi:10.1007/s12020-015-0727-2 · Cited by 63
Samson, S., Hamrahian, A. H., & Ezzat, S. (2015) · Endocrine Practice · doi:10.4158/ep15938.dsc · Cited by 69
Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas
Auriemma, R. S., Alcubierre, D. D., Pirchio, R., Pivonello, R., & Colao, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00327 · Cited by 68
“Based on this evidence, the use of dopamine agonists might be recommended even independently on PRL status, mainly in hypogonadal premenopausal women with microadenomas with no pregnancy desire who may be theoretically treated only with oral contraceptives (71).”
BackgroundShimon, I. (2018) · Neuroendocrinology · doi:10.1159/000495184 · Cited by 69
Fleseriu, M., Buchfelder, M., Cetas, J. S., Fazeli, P. K., Mallea-Gil, S., Gurnell, M., McCormack, A. I., Pineyro, M. M., Syro, L. V., Tritos, N. A., et al. (2020) · Pituitary · doi:10.1007/s11102-020-01059-7 · Cited by 64
Prolactinomas, cabergoline, and pregnancy
Glezer, A., & Bronstein, M. D. (2014) · Endocrine · doi:10.1007/s12020-014-0334-7 · Cited by 61
The risks of overlooking the diagnosis of secreting pituitary adenomas
Brue, T. C., & Castinetti, F. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0516-x · Cited by 75
Huang, W., & Molitch, M. E. (2019) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2019.05.004 · Cited by 66
Labad, J., Montalvo, I., González-Rodríguez, A., García‐Rizo, C., Crespo‐Facorro, B., Monreal, J. A., & Palao, D. J. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.04.031 · Cited by 61
Lu, Z., Sun, Y., Zhang, Y., Chen, Y., Guo, L., Liao, Y., Kang, Z., Feng, X., & Yue, W. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02027-4 · Cited by 81
“Most clinical guidelines addressing recommended only symptomatic AP-induced HPRL need to be treated [4], but the non-symptomatic HPRL also attracts a clinical attention because of its long-term outcomes.”
BackgroundThe Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
Liu, X., Tang, C., Wen, G., Zhong, C., Yang, J., Zhu, J., & Ma, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00768 · Cited by 66
di Filippo, L., Doga, M., Resmini, E., & Giustina, A. (2020) · Pituitary · doi:10.1007/s11102-020-01041-3 · Cited by 70
Paediatric Pituitary Adenomas: A Decade of Change
Guaraldi, F., Storr, H. L., Ghizzoni, L., Ghigo, E., & Savage, M. O. (2014) · Hormone Research in Paediatrics · doi:10.1159/000357673 · Cited by 58
Macroprolactinoma: a diagnostic and therapeutic update
Iglesias, P., & Díez, J. J. (2013) · QJM · doi:10.1093/qjmed/hcs240 · Cited by 68
“The probability of complete cure is greater when treatment with DA has been prolonged (>2 years) and there is no tumor rest in MRI.(37,48)”
BackgroundMethodInfluentialDefinition and diagnosis of aggressive pituitary tumors
Kasuki, L., & Raverot, G. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09531-x · Cited by 59
“However, tumor size at presentation is not linearly associated with a more aggressive behavior and this is clearly illustrated by some giant prolactinomas that present an excellent response to medical treatment with cabergoline [21, 22].”
BackgroundBoguszewski, C. L., Santos, C., Sakamoto, K. S., Marini, L. C., de Souza, A. M., & Azevedo, M. F. (2011) · Pituitary · doi:10.1007/s11102-011-0339-7 · Cited by 59
Medical therapy for spermatogenic failure
Ramasamy, R., Stahl, P. J., & Schlegel, P. N. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.63 · Cited by 61
Caputo, C., Prior, D., & Inder, W. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70212-8 · Cited by 60
Roke, Y., Buitelaar, J. K., Boot, A. M., Tenback, D. E., & van Harten, P. N. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0109 · Cited by 62
“Participants were excluded if they had a history of thyroid disorders, had syndromes or other chronic diseases affecting puberty, had endocrine disorders, used oral corticosteroids or anticonvulsants, or had a known cause of hyperprolactinemia (Verhelst and Abs 2003, Melmed et al. 2011).”
The Menstrual Disturbances in Endocrine Disorders: A Narrative Review
Naz, M. S. G., Dovom, M. R., & Tehrani, F. R. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.106694 · Cited by 85
“or induced by pharmacological medication (63).”
Radiotherapy for prolactin-secreting pituitary tumors
Olsen, L. J. S., Irizarry, L. R., Chao, S. T., Weil, R. J., Hamrahian, A. H., Hatipoğlu, B., & Suh, J. H. (2011) · Pituitary · doi:10.1007/s11102-011-0348-6 · Cited by 58
Potential Roles of Peripheral Dopamine in Tumor Immunity
Zhang, X., Liu, Q., Liao, Q., & Zhao, Y. (2017) · Journal of Cancer · doi:10.7150/jca.20850 · Cited by 61
“Moreover, DA agonists showed effectiveness in shrinking tumor size in both solid [38] and cystic [39] prolactinomas by controlling serum prolactin level [40].”
BackgroundPediatric prolactinoma: initial presentation, treatment, and long-term prognosis
Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A., & Muller, H. L. (2017) · European Journal of Pediatrics · doi:10.1007/s00431-017-3042-5 · Cited by 59
“In addition, with dopamine agonist medication, a preservation of the pituitary and visual function is made possible in many cases [1, 7, 22].”
BackgroundMontejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55
The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B
Patel, B., Koysombat, K., Mills, E., Tsoutsouki, J., Comninos, A. N., Abbara, A., & Dhillo, W. S. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad023 · Cited by 72
Nota, N. M., Dekker, M. J. H. J., Klaver, M., Wiepjes, C. M., van Trotsenburg, M., Heijboer, A. C., & den Heijer, M. (2016) · Andrologia · doi:10.1111/and.12666 · Cited by 57
“Treatment of hyperprolactinemia is recommended in symptomatic patients or in case of a macroprolactinoma (Majumdar & Mangal, 2013; Melmed et al., 2011).”
BackgroundGenetic and Epigenetic Causes of Pituitary Adenomas
Chang, M., Yang, C., Bao, X., & Wang, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.596554 · Cited by 69
Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency
Pitsava, G., Settas, N., Faucz, F. R., & Stratakis, C. A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.680609 · Cited by 61
Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia
Halperín, I., Gómez, R. C., Mouriz, M. G., & García, M. D. O. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.11.005 · Cited by 54
Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study
Soto-Pedre, E., Newey, P. J., Bevan, J. S., & Leese, G. P. (2017) · Endocrine Connections · doi:10.1530/ec-17-0171 · Cited by 54
Medical Treatment of Male Infertility
Hirsch, I. H., & Lipshultz, L. I. (1987) · Urologic Clinics of North America · doi:10.1016/s0094-0143(21)00569-3 · Cited by 54
Dopamine Agonists Can Reduce Cystic Prolactinomas
Faje, A. T., Chunharojrith, P., Nency, J., Biller, B. M. K., Swearingen, B., & Klibanski, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2008 · Cited by 55
Yao, S., Song, J., Gao, J., Lin, P., Yang, M., Zahid, K. R., Yan, Y., Cao, C., Ma, P., Zhang, H., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00742 · Cited by 56
Orija, I. B., Weil, R. J., & Hamrahian, A. H. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.07.003 · Cited by 56
2012 update in the treatment of prolactinomas
Maiter, D. M., & Primeau, V. (2012) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.03.024 · Cited by 51
Skull Base Tumors and Tumor-Like Lesions: A Pictorial Review
Kunimatsu, A., & Kunimatsu, N. (2017) · Polish Journal of Radiology · doi:10.12659/pjr.901937 · Cited by 53
Doğanşen, S. Ç., Yalın, G. Y., Tanrıkulu, S., Tekin, S., Nizam, N., Bılgıç, B., Sencer, S., & Yarman, S. (2018) · Pituitary · doi:10.1007/s11102-018-0877-3 · Cited by 57
“DA resistance was defined with a lack of response to 3–4 mg/week CAB or 20 mg/day BRC [18].”
BackgroundInfluentialProlactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
Zieliński, G., Ozdarski, M., Maksymowicz, M., Szamotulska, K., & Witek, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00439 · Cited by 51
Fukuoka, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.011 · Cited by 50
Mechanisms of Central Hypogonadism
Barber, T., Kyrou, I., Kaltsas, G., Grossman, A., Randeva, H., & Weickert, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158217 · Cited by 50
Inder, W. J., & Jang, C. (2022) · Medicina · doi:10.3390/medicina58081095 · Cited by 59
“The Endocrine Society guidelines define DA resistance as failure to achieve a normal prolactin on maximally tolerated doses of a DA and failure to achieve a 50% reduction in tumor size [96].”
BackgroundInfluentialDiagnosis and management of prolactinomas and non-functioning pituitary adenomas
Rogers, A., Karavitaki, N., & Wass, J. A. H. (2014) · BMJ · doi:10.1136/bmj.g5390 · Cited by 50
Self-citationProlactinoma and pregnancy: From the wish of conception to lactation
Maiter, D. M. (2016) · Annales d Endocrinologie · doi:10.1016/j.ando.2016.04.001 · Cited by 50
Øystese, K. A., Casar‐Borota, O., Normann, K. R., Zucknick, M., Berg, J. P., & Bollerslev, J. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00792 · Cited by 52
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas
Theiler‐Schwetz, V., Librizzi, R., Trummer, C., Theiler, G., Stiegler, C., Pieber, T. R., Obermayer-Pietsch, B. M., & Pilz, S. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9882-2 · Cited by 49
“According to the prolactinoma guidelines of the Endocrine Society, the diagnosis was based on clinical signs of hyperprolactinaemia, elevated levels of prolactin and a pituitary tumour onMRI (Melmed et al. 2011).”
BackgroundMethodGuo, X., Zhang, R., Zhang, D., Wang, Z., Gao, L., Yao, Y., Deng, K., Bao, X., Feng, M., Xu, Z., et al. (2022) · Journal of neurosurgery · doi:10.3171/2021.11.jns212137 · Cited by 53
Cabergoline Use for Pituitary Tumors and Valvular Disorders
Auriemma, R. S., Pivonello, R., Ferreri, L., Priscitelli, P., & Colao, A. A. L. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.007 · Cited by 49
Surgical Outcomes of Prolactinomas in Recent Era: Results of a Heterogenous Group
Donegan, D. M., Atkinson, J. L. D., Jentoft, M. E., Natt, N., Nippoldt, T. B., Erickson, B. J., Meyer, F. B., & Erickson, D. Z. (2016) · Endocrine Practice · doi:10.4158/ep161446.or · Cited by 48
Dopamine Agonists: From the 1970s to Today
Auriemma, R. S., Pirchio, R., Alcubierre, D. D., Pivonello, R., & Colao, A. (2019) · Neuroendocrinology · doi:10.1159/000499470 · Cited by 48
Fallah, N., Taghvaei, M., Sadaghiani, S., Sadrehosseini, S. M., Esfahanian, F., & Zeinalizadeh, M. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.08.004 · Cited by 48
Andereggen, L., Frey, J., Andres, R. H., Luedi, M. M., El‐Koussy, M., Widmer, H. R., Beck, J., Mariani, L., Seiler, R. W., & Christ, E. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01569-6 · Cited by 47
“Upper limits of PRL levels were 20 ng/mL [37].”
BackgroundDoes hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Karavitaki, N., Dobrescu, R., Byrne, J. V., Grossman, A. B., & Wass, J. A. H. (2013) · Clinical Endocrinology · doi:10.1111/cen.12124 · Cited by 47
Self-citationCabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas
Paepegaey, A. C., Salenave, S., Kamenický, P., Maione, L., Brailly‐Tabard, S., Young, J., & Chanson, P. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00038 · Cited by 49
Garcia, E. C., Naves, L. A., Silva, A. O., de Castro, L. F., Casulari, L. A., & Azevedo, M. F. (2012) · Pituitary · doi:10.1007/s11102-012-0403-y · Cited by 45
Jiang, X.-B., Li, C., He, D., Mao, Z.-G., Liu, D.-H., Fan, X., Hu, B., Zhu, Y., & Wang, H. (2013) · Pituitary · doi:10.1007/s11102-013-0495-z · Cited by 48
“Prolactinomas are the most prevalent type of secretory pituitary adenomas [1, 2], which are usually accompanied with oligomenorrhea, galactorrhea or infertility in women and decreased sexual potency in men [3].”
BackgroundSuppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
Lin, S., Leng, Z. G., Guo, Y., Cai, L., Cai, Y. C., Li, N., Shang, H. B., Le, W.-D., Zhao, W., & Wu, Z. B. (2015) · Oncotarget · doi:10.18632/oncotarget.5744 · Cited by 50
Carmina, E., Stanczyk, F. Z., & Lobo, R. A. (2019) · Yen and Jaffe's Reproductive Endocrinology · doi:10.1016/b978-0-323-47912-7.00034-2 · Cited by 36
Pharmacology of medications used for ovarian stimulation
Quaas, A. M., & Legro, R. S. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.10.002 · Cited by 55
Predictors of dopamine agonist resistance in prolactinoma patients
Vermeulen, E., D’Haens, J., Stadnik, T. W., Unuane, D., Barbé, K., Velthoven, V. V., & Gläsker, S. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0543-4 · Cited by 47
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Doğanşen, S. Ç., Selçukbiricik, Ö. S., Tanrıkulu, S., & Yarman, S. (2016) · Pituitary · doi:10.1007/s11102-016-0708-3 · Cited by 46
“Also in 2011, the guideline provided by the Endocrine Society recommended that patients who had had normoprolactinemia for at least 2 years and who had no visible tumor remnant could be candidates for DA withdrawal [23].”
BackgroundInfluentialProlactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal
Teixeira, M., Souteiro, P., & Carvalho, D. M. (2017) · Pituitary · doi:10.1007/s11102-017-0806-x · Cited by 46
“The latest guidelines on the management of prolactinomas from the Endocrine Society suggest that with close clinical and biochemical follow-up, therapy may be discontinued in patients who: (1) have been treated with DA for at least 2 years; (2) no longer have hyperprolactinemia; (3) who have no visible tumour on MRI […”
BackgroundInfluentialImpact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal
Santharam, S., Fountas, A., Tampourlou, M., Arlt, W., Ayuk, J., Gittoes, N. J. L., Toogood, A. A., & Karavitaki, N. (2018) · Clinical Endocrinology · doi:10.1111/cen.13765 · Cited by 46
Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention
Yoo, F., Chan, C. K., Kuan, E. C., Bergsneider, M., & Wang, M. B. (2017) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0037-1615748 · Cited by 46
The safety of available treatments of male hypogonadism in organic and functional hypogonadism
Corona, G., Rastrelli, G., Reisman, Y., Sforza, A., & Maggi, M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1424831 · Cited by 50
“If ‘organic’ HG means that it is an irreversible condition, we should consider the T deficit associated with prolactinomas as a ‘functional’ HG; in fact, it is often reversed by a correct dopaminergic therapy of the tumor [82].”
BackgroundDopamine Agonists for Pituitary Adenomas
Cooper, O. B., & Greenman, Y. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00469 · Cited by 47
Corynebacterium kroppenstedtii: a challenging culprit in breast abscesses and granulomatous mastitis
Saraiya, N., & Corpuz, M. O. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000541 · Cited by 46
Liu, W. L., Zahr, R., McCartney, S., Cetas, J. S., Dog⫧an, A., & Fleseriu, M. (2018) · Pituitary · doi:10.1007/s11102-018-0898-y · Cited by 45
The pituitary tumour epigenome: aberrations and prospects for targeted therapy
Yacqub‐Usman, K., Richardson, A., Duong, C. V., Clayton, R. N., & Farrell, W. E. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.54 · Cited by 50
Prolactinomas in pregnancy: considerations before conception and during pregnancy
Glezer, A., & Bronstein, M. D. (2019) · Pituitary · doi:10.1007/s11102-019-01010-5 · Cited by 45
Lin, S., Zhang, A., Zhang, X., & Wu, Z. B. (2019) · Neuroendocrinology · doi:10.1159/000504000 · Cited by 49
Pregnancy and Tumor Outcomes in Women with Prolactinoma
Araujo, B., Belo, S., & Carvalho, D. M. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-112861 · Cited by 43
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma
Fukuhara, N., Nishiyama, M., & Iwasaki, Y. (2022) · Cancers · doi:10.3390/cancers14153604 · Cited by 43
“Medical therapy with a dopamine agonist (DA) is highly effective in the majority of cases [1,2].”
BackgroundInfluentialManagement of antipsychotic-induced hyperprolactinemia
Tewksbury, A., & Olander, A. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.07.185 · Cited by 57
“If discontinuation is not possible, a pituitary magnetic resonance imaging is recommended to rule out a pituitary or hypothalamic mass.(8)”
Background
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.